JAK3 and ulcerative colitis: Tofacitinib, which primarily inhibits JAK1 and JAK3 with partial JAK2 inhibition, is approved for conditions like rheumatoid arthritis (RA) and ulcerative colitis (UC), but has emerging applications in dermatologic diseases.